scholarly journals New therapy options for patients with eosinophilic type of severe bronchial asthma

2020 ◽  
pp. 111-116
Author(s):  
G. L. Ignatova ◽  
V. N. Antonov ◽  
E. V. Blinova ◽  
I. V. Grebneva ◽  
E. V. Sheklanova
Keyword(s):  
Decision Making ◽  
Severe Asthma ◽  
Bronchial Asthma ◽  
Clinical Studies ◽  
Clinical Characteristics ◽  
Biological Therapy ◽  
Efficacy And Safety ◽  
Therapy Options ◽  
New Therapy ◽  
Chelyabinsk Region

The article provides data on the epidemiology of severe asthma. It defines the phenotype and endotype of bronchial asthma and classifies BA according to phenotype/endotype. The features of the eosinophilic phenotype of severe bronchial asthma are considered. Clinical characteristics of the patient corresponding to the prescription of benralizumab are presented. The algorithm of decision making by a doctor-therapist about patients’ referral to a pulmonologist for consideration of the biological therapy issue is given. The results of the main clinical studies to assess the efficacy and safety of benralizumab in patients with severe eosinophilic bronchial asthma: SIROCCO, CALIMA, ZONDA, BORA are described. The experience of using various biological preparations for the treatment of severe asthma in Chelyabinsk and the Chelyabinsk Region has also been summarized.

scholarly journals Monoclonal antibodies in the treatment of bronchial asthma

2018 ◽  
Vol 15 (3) ◽  
pp. 5-15
Author(s):  
N I Ilina ◽  
O M Kurbacheva
Keyword(s):  
Monoclonal Antibodies ◽  
Genetic Markers ◽  
Bronchial Asthma ◽  
Clinical Characteristics ◽  
Standard Treatment ◽  
Biological Therapy ◽  
Resistance Response ◽  
Definition Of ◽  
Selection Of Patients ◽  
Selection Of

The article discusses different phenotypes of heterogeneous bronchial asthma (BA), methods of identification of patients with severe bronchial asthma, based on clinical characteristics, biological and genetic markers. Definition of phenotypes/ endotypes of BA contributes to better understanding of the nature of the disease and is feasible for development of an individual approach to therapy, because some types of BA may differ in resistance response to the standard treatment. The article gives an overview of modern research focused on the use of monoclonal antibodies in the treatment of BA. It discusses the algorithm of selection of patients with severe BA for prescribing of biological therapy.

scholarly journals Comparing Patient Characteristics, Clinical Outcomes, and Biomarkers of Severe Asthma Patients in Taiwan

Biomedicines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 764
Author(s):  
Shih-Lung Cheng ◽  
Kuo-Chin Chiu ◽  
Hsin-Kuo Ko ◽  
Diahn-Warng Perng ◽  
Hao-Chien Wang ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Clinical Characteristics ◽  
Linear Models ◽  
Patient Characteristics ◽  
Emergency Department Visits ◽  
Receiver Operating Characteristic Curves ◽  
Increased Risk ◽  
Significant Difference ◽  
Asthma Patients ◽  
Patients At Risk

Purpose: To understand the association between biomarkers and exacerbations of severe asthma in adult patients in Taiwan. Materials and Methods: Demographic, clinical characteristics and biomarkers were retrospectively collected from the medical charts of severe asthma patients in six hospitals in Taiwan. Exacerbations were defined as those requiring asthma-specific emergency department visits/hospitalizations, or systemic steroids. Enrolled patients were divided into: (1) those with no exacerbations (non-exacerbators) and (2) those with one or more exacerbations (exacerbators). Receiver operating characteristic curves were used to determine the optimal cut-off value for biomarkers. Generalized linear models evaluated the association between exacerbation and biomarkers. Results: 132 patients were enrolled in the study with 80 non-exacerbators and 52 exacerbators. There was no significant difference in demographic and clinical characteristics between the two groups. Exacerbators had significantly higher eosinophils (EOS) counts (367.8 ± 357.18 vs. 210.05 ± 175.24, p = 0.0043) compared to non-exacerbators. The optimal cut-off values were 292 for EOS counts and 19 for the Fractional exhaled Nitric Oxide (FeNO) measure. Patients with an EOS count ≥ 300 (RR = 1.88; 95% CI, 1.26–2.81; p = 0.002) or FeNO measure ≥ 20 (RR = 2.10; 95% CI, 1.05–4.18; p = 0.0356) had a significantly higher risk of exacerbation. Moreover, patients with both an EOS count ≥ 300 and FeNO measure ≥ 20 had a significantly higher risk of exacerbation than those with lower EOS count or lower FeNO measure (RR = 2.16; 95% CI, 1.47–3.18; p = < 0.0001). Conclusions: Higher EOS counts and FeNO measures were associated with increased risk of exacerbation. These biomarkers may help physicians identify patients at risk of exacerbations and personalize treatment for asthma patients.

New insight into the clinical characteristics of adults vs children with severe asthma

2002 ◽  
Vol 109 (1) ◽  
pp. S353-S353 ◽  
Author(s):  
Henry Avner Jenkins ◽  
Stanley J Szefler ◽  
Ronina A Covar ◽  
Monica Jones ◽  
Eleanor E Brown ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Clinical Characteristics ◽  
Insight Into

Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review

2018 ◽  
Vol 39 (1) ◽  
pp. 47-58 ◽  
Author(s):  
Ana Urruticoechea-Arana ◽  
Tatiana Cobo-Ibáñez ◽  
Virginia Villaverde-García ◽  
Montserrat Santos Gómez ◽  
Estíbaliz Loza ◽  
...  
Keyword(s):  
Systematic Review ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Biological Therapy ◽  
Behçet's Disease ◽  
Immunomodulatory Drugs ◽  
Efficacy And Safety ◽  
Behcet's Disease

scholarly journals ASMANEX TWISTHALER - THE DRUG OF CHOICE AMONG INHALED CORTICOSTEROIDS

2013 ◽  
Vol 10 (6) ◽  
pp. 51-57
Author(s):  
T V Latysheva ◽  
E A Latysheva ◽  
O V Shubina
Keyword(s):  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Control Methods ◽  
Efficacy And Safety ◽  
Prior Therapy ◽  
Asthma Symptoms ◽  
Drug Of Choice ◽  
Systemic Corticosteroids ◽  
Before And After ◽  
Baseline Therapy

Goals. To reveal the clinical efficacy and safety of Asmanex in patients with moderate and severe bronchial asthma (BA), treated with inhaled and/or systemic glucocorticosteroids (GCS), depending on the severity and level of control. Methods. 40 patients (age 18 to 65 years) were treated with Asmanex with equivalent to prior therapy with inhaled corticosteroids (ICS) doses or in combination with systemic corticosteroids prior therapy (without increasing the dose of systemic corticosteroids) for 3 months. Efficacy was assessed before and after the treatment on a background of Asmanex treatment by the need of additional using of agonists of β 2-adrenoreceptors, severity of daytime and nighttime asthma symptoms, dynamics of spirometry parameters. The efficacy of Asmanex was compared with the original baseline therapy of other inhaled corticosteroids at equivalent doses using the new delivery system.

scholarly journals Severe eosinophilic bronchial asthma: new therapeutic options

2018 ◽  
pp. 44-52 ◽  
Author(s):  
N. M. Nenasheva
Keyword(s):  
Monoclonal Antibodies ◽  
Severe Asthma ◽  
Bronchial Asthma ◽  
Biological Agents ◽  
Therapeutic Options ◽  
Clinical Use ◽  
Eosinophilic Asthma ◽  
Interleukin 5 ◽  
Severe Eosinophilic Asthma

Eosinophilic asthma is a common phenotype of severe asthma, occurring in at least half of patients. In recent years, there have been significant changes in the approaches to the treatment of severe bronchial asthma and, above all, eosinophilic asthma. The article discusses the role of eosinophils in the pathogenesis of severe asthma, the detection of the phenotype of severe eosinophilic asthma, and modern approaches to targeting severe asthma with an eosinophilic phenotype using biological agents. A special emphasis is placed on preparations of monoclonal antibodies to interleukin-5, in particular, mepolizumab, recently approved for clinical use in our country.

scholarly journals Diabetes, hyperglycemia and its role in fitness for work

2020 ◽  
Author(s):  
Mirsaeed Attarchi ◽  
Seyed Mohammad Seyedmehdi
Keyword(s):  
Decision Making ◽  
Scientific Evidence ◽  
Review Article ◽  
Diabetic Patients ◽  
Efficacy And Safety ◽  
Ability To Work ◽  
Personal Risk ◽  
Fitness For Work ◽  
The World ◽  
Prevalent Disease

Introduction: Diabetes is a prevalent disease in our country and in the world. Hyperglycemia complications can impact on ability to work. Decision making about fitness for work in diabetic patients is important and complicated. The aim of this study was assessment scientific evidence and present suitable approach for fitness for work in diabetic patients. Methods: In this review article the last evidence from Scopus, Science Direct, Pub Med, Google Scholar, SID and Magiran Data Base was evaluated and different aspects of fitness for work in hyperglycemia of diabetics of diabetic patients was analyzed. Results: Assessment of personal risk and diabetic patient abilities in comparison with inherent requirements of the job is important in decision making about fitness for work. Most of these patients can work and have acceptable efficacy and safety in most of the jobs. Conclusion: In most of job situations, with support of the employer and job environment modifications, diabetic patients can work with acceptable efficacy and safety.

scholarly journals Therapeutic Depletion of Axotomy Competent Cells in Amyotrophic Lateral Sclerosis (ALS)

2019 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Amyotrophic Lateral Sclerosis ◽  
Protein Networks ◽  
Large Protein ◽  
Anatomical Structures ◽  
Therapy Options ◽  
New Therapy ◽  
Competent Cells ◽  
Health And Disease ◽  
Insight Into ◽  
Lateral Sclerosis

The present paper addresses anatomically resolved protein networks by using the Imaging Cycler Microscopy (ICM/TIS) [1,2]. ICM is capable of resolving protein networks in intact anatomical structures at a power of combinatorial molecular resolution of 65,553k , where k is the number of co-mapped proteins, e.g. 100 proteins [1-4]. This method provides insight into the laws of the spatial communication of large protein networks in health and disease, which is essential for new therapy options in diseases.

Sign in / Sign up

Export Citation Format

Share Document